Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Journal of Clinical Oncology

• Publication date

  1987-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1987.5.5.722PMID 3572463
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study.

  1987cited by this paper
• Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy.

  1985cited by this paper
• A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia.

  1984cited by this paper
• Relationship of the growth of leukemic cells in vitro to the outcome of therapy for acute nonlymphocytic leukemia.

  1984cited by this paper
• Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside

  1984cited by this paper
• Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease.

  1984cited by this paper
• A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.

  1984cited by this paper
• Identification of early relapsing patients with adult acute nonlymphocytic leukemia by bone marrow biopsy after initial induction chemotherapy.

  1984cited by this paper
• Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure

  1983cited by this paper
• Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association.

  1983cited by this paper
• Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: utility of day 6 bone marrow biopsy.

  1983cited by this paper
• Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.

  1982cited by this paper
• The treatment of acute myelocytic leukemia in patients 30 years of age and younger

  1982cited by this paper
• A four‐year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia

  1981cited by this paper
• Prevention of infection and bleeding in leukemic patients receiving intensive remission maintenance therapy.

  1981cited by this paper
• Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

  1981cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper
• Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens.

  1979cited by this paper
• Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia.

  1979cited by this paper
• Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group

  1976cited by this paper

• Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients.

  2018cites this paper
• study of 9,729 patients diagnosed in Sweden 1973-2005 Improved patient survival for acute myeloid leukemia: A population-based

  2013cites this paper
• complete responses to high-dose cytarabine Short remission durations in therapy-related leukemia despite cytogenetic

  2011cites this paper
• untreated acute myeloid leukemia: a Southwest Oncology Group cytosine arabinoside with daunorubicin in patients with previously A randomized investigation of high-dose versus standard-dose

  2011cites this paper
• Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973–2001, a population‐based study

  2010cites this paper
• A CLINICAL AND EPIDEMIOLOGICAL STUDY

  2010cites this paper
• Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005.

  2009cites this paper
• Langzeitergebnisse nach Induktionsbehandlung der akuten myeloischen Leukämie mit Cytosinarabinosid und Idarubicin

  2008cites this paper
• Improved patient survival for acute myeloid leukemia: A population-based study of 9,729 patients diagnosed in Sweden 1973-2005 Running title: Survival in acute myeloid leukemia

  2008cites this paper
• Short‐term remission induction and consolidation therapy for adult acute myelogenous leukemia

  2006cites this paper
• Curing acute myelogenous leukemia: still a major challenge.

  2005cites this paper
• Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside

  2004cites this paper
• Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission

  2003cites this paper
• Time sequential high dose of Cytarabine in acute myelocytic leukemia

  2003cites this paper
• Age and Cytogenetics as Predictors of Event Free Survival in Patients with Acute Non-Lymphocytic Leukemia Receiving High Dose Cytosine Arabinoside and Daunorubicin as Consolidation Chemotherapy

  2001cites this paper
• Transfusion iron overload in adults with acute leukemia: manifestations and therapy.

  2000cites this paper
• Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.

  1999cites this paper
• Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.

  1998cites this paper
• Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin

  1998cites this paper
• Control of Leukemia Proliferation in vivo in Patients: In vivo Cytokine Production

  1998cites this paper
• Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group

  1998cites this paper
• Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.

  1998cites this paper
• Prospective Comparison of Allogeneic Bone Marrow Transplantation, Intensive Consolidation Chemotherapy, and Unpurged Autologous Bone Marrow Transplantation as Post-Remission Therapy in Adult Acute Myeloid Leukemia

  1997cites this paper
• Long-term Follow Up of a Prospective Multicenter Trial with a High-Dose Cytosine Arabinoside and Daunorubicin Postremission Therapy in Adults with De Novo Acute Myeloid Leukemia

  1997cites this paper
• Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia.

  1997cites this paper
• Survival in 86 patients, aged 15–60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990–1995

  1997cites this paper
• Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

  1997cites this paper
• Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission

  1997cites this paper
• The treatment of adult acute myeloid leukemia.

  1997cites this paper
• Intensified Induction and Post-Remission Therapy for Acute Myeloid Leukaemia.

  1996cites this paper
• High-dose chemotherapy in adult acute myeloid leukemia: rationale and results.

  1996cites this paper
• A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.

  1996cites this paper
• Treatment of acute myelogenous leukaemia in patients aged 50–65: idarubicin is more effective than zorubicin for remission induction and prolonged disease‐free survival can be obtained using a unique consolidation course

  1996cites this paper
• Etoposide and mitoxantrone as a second cycle of consolidation therapy following high dose cytosine arabinoside and daunorubicin in patients with acute non-lymphocytic leukemia in remission: a pilot study.

  1996cites this paper
• Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.

  1996cites this paper
• Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age?

  1995cites this paper
• Improved survival for patients with acute myelogenous leukemia.

  1995cites this paper
• Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).

  1995cites this paper
• A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.

  1995cites this paper
• High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia

  1995cites this paper
• Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.

  1995cites this paper
• Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow.

  1994cites this paper
• Acute myeloid leukemia in manitoba

  1994cites this paper
• Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia

  1994cites this paper
• The leukemias.

  1994cites this paper
• Long-Term Outcome of Postremission Chemotheratw for Adults with Acute

  1994cites this paper
• 1.全身性腫瘍としての白血病の化学療法,最近の進歩

  1994cites this paper
• Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.

  1994cites this paper
• The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS and MYC proto-oncogenes.

  1994cites this paper
• Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

  1994cites this paper
• Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.

  1994cites this paper
• Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.

  1993cites this paper
• Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.

  1993cites this paper
• Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen.

  1993cites this paper
• Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.

  1993cites this paper
• [Treatment of acute myeloblastic leukemia].

  1993cites this paper
• Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen

  1993cites this paper
• ACUTE MYELOID LEUKAEMIA IN THE ELDERLY: BIOLOGY AND TREATMENT

  1993cites this paper
• Intensive sequential post-induction therapy for adults with acute myelogenous leukemia in first remission: long-term follow-up and results.

  1992cites this paper
• Strategies in the treatment of acute myelogenous leukemia.

  1992cites this paper
• State of the Art and Future Prospects of the Treatment of Acute Myeloid Leukemia

  1992cites this paper
• Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission.

  1992cites this paper
• Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia

  1992cites this paper
• Chemotherapy of acute myelogenous leukemia. A review.

  1992cites this paper
• Therapy of acute myelogenous leukemia.

  1992cites this paper
• Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.

  1992cites this paper
• First successful unrelated bone marrow transplant in Canada: A look at the longest surviving recipient.

  1992cites this paper
• Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Medical Research Council Working Party on Childhood Leukaemia.

  1992cites this paper
• Varying intensity of postremission therapy in acute myeloid leukemia.

  1992cites this paper
• [The strategy for the therapy of acute myeloid leukemias in adults].

  1992cites this paper
• Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990.

  1992cites this paper
• A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia: a report of the Italian Cooperative Group GIMEMA

  1992cites this paper
• Post-remission therapy of acute myelocytic leukemia in adults: curability breeds controversy.

  1992cites this paper
• Double intensive consolidation chemotherapy in adult acute myeloid leukemia.

  1991cites this paper
• Circulating immune complexes correlate with remission duration in acute myeloid leukemia.

  1991cites this paper
• Acute myeloid leukemia in the elderly: biological features and search for adequate treatment

  1991cites this paper
• Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.

  1991cites this paper
• Double intensive consolidation chemotherapy in adult acute myeloid leukemia.

  1991cites this paper
• Determinants of response and prediction of response to chemotherapy in acute myelogenous leukemia.

  1991cites this paper
• Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.

  1990cites this paper
• Acute monocytic leukaemia in adults: treatment and prognosis in 99 cases

  1990cites this paper
• Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.

  1990cites this paper
• Acute Leukemias II

  1990influential citation
• The role of timing of high‐dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia

  1990cites this paper
• Post-remission treatment in acute myeloid leukemia: chemotherapy or autologous or allogeneic bone marrow transplantation.

  1990cites this paper
• Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.

  1990cites this paper
• Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.

  1990cites this paper
• Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia.

  1990cites this paper
• Chemotherapy of the Leukaemias

  1990cites this paper
• Results and prognosis of acute non-lymphocytic leukemia in adults. A retrospective study of 319 patients between 1977-1987.

  1990cites this paper
• MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia

  1990cites this paper
• Autologous bone marrow transplantation in the treatment of acute myeloid leukemia: the Dartmouth experience and a review of literature.

  1990cites this paper
• Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.

  1990cites this paper
• High dose cytarabine in acute myelogenous leukemia.

  1989cites this paper
• Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study

  1989cites this paper
• High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia.

  1989cites this paper
• Advances in the therapy of acute nonlymphocytic leukemia.

  1989cites this paper
• High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results.

  1989cites this paper
• New developments in post-induction therapy for acute myeloblastic leukaemia.

  1989cites this paper
• Sodium protects against nephrotoxicity in patients receiving amphotericin B.

  1989cites this paper